Simultaneously, it engages the glucose-dependent insulinotropic polypeptide receptor (GIPR), which was historically considered metabolically dormant but now recognized for synergistic effects on energy expenditure and weight regulation
This unique combination enhances its ability to regulate appetite, promote satiety, and support weight loss more effectively than medications that only target one pathway
CagriSema combines semaglutide with cagrilintide, an amylin analog, showing 20.4% weight loss in recent Phase 3 trials
The mechanisms of these drugs, which include slowing gastric emptying and signaling fullness to the brain, work synergistically with a high-protein diet to enhance these effects
Build your payment and merchant strategy now Weight loss is one of the most scrutinized advertising and payments categories online